Alembic Pharmaceuticals

Please find enclosed Newspaper Publication regarding Second 100 Day-Campaign of "Saksham Niveshak".

17 Apr, 2026 | 03:47pm • Source: BSE

Alembic Pharmaceuticals Limited receives USFDA approval for Methotrexate Injection USP.

16 Apr, 2026 | 11:14am • Source: BSE

Please find attached Certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018 for the quarter ended 31st March, 2026.

08 Apr, 2026 | 06:09pm • Source: BSE

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dapagliflozin Tablets, 5 mg and 10 mg.

07 Apr, 2026 | 12:25pm • Source: BSE

The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CRA Family Trust

06 Apr, 2026 | 02:38pm • Source: BSE

Please find enclosed herewith the Intimation regarding appointment of Mr. Chirayu Amin as Executive Chairman of the Company

01 Apr, 2026 | 07:07pm • Source: BSE

Please find enclosed herewith the Intimation regarding Relinquishment from the position of CEO of the Company

01 Apr, 2026 | 07:03pm • Source: BSE

Please find enclosed herewith the Intimation regarding Re-appointment of Mr. Pranav Amin as Managing Director of the Company

01 Apr, 2026 | 06:57pm • Source: BSE

Appointment of Mr. Rajkumar Baheti as Non Executive Non Independent Director of the Company

01 Apr, 2026 | 02:15pm • Source: BSE

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 12.5 mg.

27 Mar, 2026 | 03:22pm • Source: BSE

Intimation of Closure of Trading Window.

27 Mar, 2026 | 03:06pm • Source: BSE

Intimation of One on One Investor meet

20 Mar, 2026 | 11:47am • Source: BSE

Intimation of One on One Investor Meet

06 Mar, 2026 | 11:56am • Source: BSE

PFA the press release

06 Mar, 2026 | 09:03am • Source: BSE

Intimation of One on One Investor Meet

04 Mar, 2026 | 07:44pm • Source: BSE

Please find attached Newspaper Publication

02 Mar, 2026 | 06:51pm • Source: BSE

Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated February 26, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Lamotrigine...

26 Feb, 2026 | 11:42am • Source: NSE

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg.

26 Feb, 2026 | 10:42am • Source: BSE

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Efinaconazole Topical Solution, 10%.

24 Feb, 2026 | 02:30pm • Source: BSE

Newspaper Publication of Unaudited Financials Results for the Quarter and Nine Months Ended 31st December, 2025

06 Feb, 2026 | 03:20pm • Source: BSE